Member Info for EyeGuy

they should be looking at $50-250 million as an initial upfront payment from a major. That's what is on the presentation.

market for hormone therapy drugs which lose their resistance are circa $10 billion annually. After they stop working then nothing else available. These results are amazing. I can see the big pharmas looking now.

Multibagger coming up. This will be ending the day 200% up imo. Huge news

wow wow wow. Just added £3k at 29p. This should be 3 - 4 bagging from here. Huge results. Broker target £1.13

still watching and adding personally

Wassatt- good afternoon. Doing good thanks pal. Should bounce this afternoon here. I’ll be making money from my 0.30 entry this afternoon imo

Going back up quickly now. Think mms are taking the piss. Think this will
Close 0.40 ish

took another k at 0.307. will bounce strongly imo

probably be heading back that way today imo

yep. took some at 0.30p. easy 30-50% from here imo. drop overdone

in at 0.30p. finish in the 0.4's I reckon.

nice. ticking up. strong afternoon coming

imo dyor

I make it 70 trades so far. LSE is wrong. Looking good guys. expect an afternoon rush

Imo if end point reached this will be over 50p like a shot.
They already have a positive response in 40% of the patients from the interim readout.
If results are exceptional then likely you will get the £1.13 at some point
Dyor

Summary:
- news due on phase 2 readout next week as per rnd
- in intermedia readout, 8 out the 20 subjects with metastatic breast cancer showed a positive response to SFX-01
- drugs used before SFX-01 will command annual revenues of $10 billion within 2 years.
- SFX-01 also used in phase 2 subarachnoid haemorrhage. Full readout due summer
- company presentation suggests initial payments of between $50 and $250 by Pharma majors if successful plus double digit royalties.
- freefloat circa 36%. Lots of II’s holding

Dyor

Wel I said 20p and it’s well over that.
25p tomorrow imo at least. Very limited stock. Broker target £1.13
Dyor

26% up finish. This site is wrong

and from interim update:
SFX-01isprovingtobewelltoleratedwithnosafetyconcernsarising ? SFX-01showsencouragingearlysignsofanti-tumouractivity: - Ofthefirst 20patients,4patientshadtheirprogressive diseasestabilisedfor atleast24weeksand afurther2for18weeks - Twopatientsthat,atonescan,showedapartialresponse(i.e.tumourshrinkageover30%) ? PrincipalInvestigator,DrSachaHowelloftheChristieHospital,UK,said: “The design of the STEM study, adding the drug to endocrine therapy on which a patient’s cancer was progressing, sets a high bar for SFX-01. In light of this, these interim results are highly encouraging. Objective responses indicate activity in this setting, and disease stabilisation for 6-12+ months representsclinicallymeaningfulprolongationofresponse. . .”

no stock pal: read this
Incidence of ER+ metastatic breast cancer is approximately 130,0001 in US and Europe ? CDK4/6 inhibitors are now first line treatment, in combination with hormone therapy ? Pfizer (Ibrance®/palbociclib), Novartis (Kisqali®/ribociclib) and Eli Lilly (Versenio®/abemaciclib ) are the key players with sales forecasts of $4.4bn, $0.3bn and $0.17bn respectively in 2018e2 ? CDK4/6 inhibitor sales forecast to reach c.$9bn by 2021e2 ? With hormone therapy after c.25 months on average, patients become resistant to CDK4/6 inhibitors ? Potential of SFX-01 after CDK4/6 inhibitor therapy: a unique mechanism of action and a more favourable side-effect profile

28% up now pal. Don't forget SFX-01 has multi uses. Next readouts for Subarachnoid haemorrhage due Late summer. This drugs for metastatic breast cancer used prior to SFX-01 market is worth $10 billion annually
should be a good week